Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Autoimmune and Inflammatory Disorders, and Biosimilars and Bioanalytical Methods.
International Magnetic Resonance Imaging Consensus for Use in Luminal Crohn’s Disease Trials and Clinical Practice
Bowel Urgency Improvement Correlates With Clinical, Biochemical, and Intestinal Ultrasound Improvements in Inflammatory Bowel Disease: A Cross Sectional Multicenter Study.
Long-term safety of ustekinumab in Crohn's disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data.
A descriptive comparison of phase 3 results and head-to-head trials in inflammatory bowel diseases.
Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States.
Vedolizumab clinical decision support tool predicts clinically relevant targets in patients with Crohn's disease.
Beyond class effects: moving towards drug-level precision in inflammatory bowel disease therapy.
Digital twins in IBD-bridging data, biology and trial innovation.
Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study.
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial.
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's disease.
Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis.
IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease.
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib.
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.
Tools and advanced imaging technologies for assessing intestinal epithelial barrier integrity: a systematic review.
Building a Robust Investigator-Initiated Platform: The I-CARE Experience.
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus
Precision nutrition for the prevention and management of inflammatory bowel disease
Understanding the therapeutic toolkit for inflammatory bowel disease.
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response.
Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A <scp>GETAID</scp> Multicentre Cohort Study
<i>In vitro</i> microbiota model recapitulates and predicts individualised sensitivity to dietary emulsifier.
IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials
Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey.